ATLANTA, GA--(Marketwire - Dec 5, 2012) -  Sanguine Corporation (OTCBB: SGUI), an innovator in perfluorocarbon ("PFC") based therapies, is pleased to announce that it has entered into a Letter of Intent (LOI) to purchase New Alliance Pharmaceuticals, Inc. ("New Alliance"). New Alliance holds an exclusive license for OxygentT, the most clinically advanced perfluorocarbon (PFC) product in the world, with 20 clinical studies and ~250 preclinical studies already completed.

View More